相关实验视频

Updated: May 8, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

在代谢功能障碍相关的脂肪肝炎中,候选生物标志物和免疫透景观的全面分析

Zhangliu Jin¹, Jianyun Cao², Zhaoxun Liu^3,4

¹Department of General Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.

Metabolism open

|April 28, 2025

概括

这项研究确定了像FN1和RHOA这样的关键免疫相关基因 (IR-DEG),这些基因显示出诊断和预测代谢功能障碍相关的脂肪肝炎 (MASH) 的潜力. 这些发现可能会为这种不断增长的肝病带来新的治疗点.

科学领域:

免疫学免疫学免疫学
肝病学肝病学是一种肝病学.
基因组学就是基因组学.

背景情况:

代谢功能障碍相关的脂肪肝炎 (MASH) 是一个日益严重的健康问题,其复杂的病理生理学涉及免疫反应.
目前对MASH的药理疗法有限,这凸显了迫切需要新型免疫代谢标的迫切需要.
了解免疫系统在MASH中的作用对于开发有效干预措施至关重要.

研究的目的:

识别与MASH相关的枢纽免疫相关基因 (IR-DEGs).
发现MASH患者潜在的诊断和预测生物标志物.
在MASH中探索已识别的基因在免疫平衡中的作用.

主要方法:

对GSE164760数据集的分析,以确定差异表达基因 (DEG).
将DEG与免疫相关基因进行比较,以确定IR-DEG.
蛋白与蛋白相互作用网络分析以确定枢纽IR-DEG,然后在独立数据集 (GSE48452,GSE63067) 和小鼠MASH模型中进行验证.

主要成果:

确定了91个IR-DEG (61个上调,30个下调).
已经确定了八个枢纽的IR-DEG:FN1,RHOA,FOS,PDGFRα,CCND1,PIK3R1,CSF1和FGF3. 这些都是FN1,RHOA,FOS,PDGFRα,CCND1,PIK3R1和FGF3.
这些枢纽基因表现出显著的诊断潜力,与免疫细胞透相关,并在队列和小鼠模型中得到验证.

结论:

已确定的枢纽IR-DEGs (FN1,RHOA,FOS,PDGFRα,CCND1,PIK3R1,CSF1,FGF3) 是MASH诊断和预后的有希望的生物标志物.
这些基因可能在MASH中调节免疫平衡中发挥关键作用.
对这些免疫代谢标的进一步研究可能为新型MASH疗法铺平道路.

关键词:

不同表达的基因.免疫系统的透.肝脏肝脏肝脏肝脏与代谢功能障碍相关的脂肪肝炎.预测预后预测预测

更多相关视频

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...